Biotech M&A Anomalies With Allan Shaw
Business Of Biotech
00:00
Is It Going to Take a Longer Time to Get There?
Small molecules are generally simpler than the complexity associated with more complex modalities. Anybody production is certainly much more costly and elongated, you get into cell or gene therapy, that's another kettle of fish as well. And it's I think being relevant is important now, because there's an opportunity cost for investors. So therefore, small molecules are certainly have some benefit in terms of how quickly you can develop them.
Transcript
Play full episode
